Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal
NCT ID: NCT00333060
Last Updated: 2008-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
164 participants
INTERVENTIONAL
2005-11-30
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OT-551 ophthalmic solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to be screened for eligibility and begin dosing 7-10 days in advance of the surgery
* Best corrected ETDRS visual acuity equivalent to Snellen 20/400 or better in the surgical eye and 20/100 or better in the fellow eye
Exclusion Criteria
* Cataract (greater than slight opacity or thickness) in the surgical eye
* Any other retinal abnormality which may be vision-threatening
* Serious heart, kidney, or liver disease
* Recent ophthalmic surgery (within 6 months) or ocular infection (within 30 days)
* Poorly controlled diabetes or unstable glaucoma
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Othera Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peoria, Arizona, United States
Beverly Hills, California, United States
Sacramento, California, United States
Denver, Colorado, United States
Miami, Florida, United States
Tallahassee, Florida, United States
Chicago, Illinois, United States
Joliet, Illinois, United States
Baltimore, Maryland, United States
Cherry Hill, New Jersey, United States
Forrest Hills, New Jersey, United States
New York, New York, United States
Cleveland, Ohio, United States
Bala-Cynwyd, Pennsylvania, United States
West Chester, Pennsylvania, United States
Abilene, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OT-551-002
Identifier Type: -
Identifier Source: org_study_id